Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
The Food Effect on Pharmacokinetics Study of QLC1101 in Healthy Subjects
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06980909
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Phase 1
Not yet recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: QLC1101+QL1203Drug: QLC1101+QL2107Drug: QLC1101+QL1706Drug: QLC1101+docetaxel
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06949761
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: QLS31905 for InjectionDrug: QL2107 Injection
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06942767
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
Phase 4
Not yet recruiting
- Conditions
- Transthyretin Amyloid Polyneuropathy
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06940336
Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: QLS5132
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT06932094
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06911827
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Phase 3
Not yet recruiting
- Conditions
- Postmenopausal Women With Osteoporosis
- Interventions
- Drug: QLG2128
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 282
- Registration Number
- NCT06898060
A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT06872580
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
Phase 3
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: QL2108 injection
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 520
- Registration Number
- NCT06884891
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Phase 3
Not yet recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: QLM3003 PlaceboDrug: 1.5% QLM3003 ointmentDrug: 2% QLM3003 ointment
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06880276
© Copyright 2025. All Rights Reserved by MedPath